Important: Retatrutide is an investigational medication currently in Phase 3 clinical trials. It has not been approved by the U.S. Food and Drug Administration (FDA) and is not available for prescription. The information in this article is for educational purposes only, based on published clinical trial data, and does not constitute medical advice or promotion of an unapproved therapy. Perimenopause treatment decisions should be made with a licensed medical provider.
Retatrutide & Women's Health
PERIMENOPAUSE WEIGHT GAIN
You didn't fail at weight loss. Your hormones changed the rules.
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC · Updated March 25, 2026
Book a Consultation
WHAT'S ACTUALLY HAPPENING
You didn't get lazy at 42. Your estrogen dropped and your metabolism followed.
Perimenopause typically begins in a woman's early-to-mid 40s, though it can start in the late 30s. It's the 4–10 year transition before menopause during which ovarian function declines and hormonal output becomes erratic. Estrogen doesn't just drop gradually — it swings. Some months it spikes higher than normal, other months it craters. Progesterone declines more steadily. The result is metabolic chaos that most women experience as sudden, unexplained weight gain — particularly around the abdomen.
This isn't motivational failure. It's endocrinology. Here's what's happening at the cellular level:
Insulin Sensitivity Drops
Estrogen plays a direct role in insulin signaling. It helps muscle and liver cells absorb glucose efficiently. As estrogen declines, those cells become more insulin resistant. Your body compensates by producing more insulin. Elevated insulin is one of the most potent signals for fat storage — particularly visceral fat around the organs. This is why women in perimenopause gain weight in the abdomen specifically, even if they've always carried weight in the hips and thighs. The distribution pattern changes because the hormonal environment changes.
Visceral Fat Storage Increases
Estrogen is protective against visceral adiposity. It promotes subcutaneous fat storage (under the skin, less metabolically dangerous) over visceral storage (around the organs, metabolically active and inflammatory). When estrogen drops, the body shifts to a male-pattern fat distribution: more visceral, more abdominal. Visceral fat is not just cosmetically frustrating — it actively secretes inflammatory cytokines, worsens insulin resistance, and increases cardiovascular risk. It's a self-reinforcing cycle: less estrogen leads to more visceral fat, which leads to more inflammation, which leads to more insulin resistance, which leads to more fat storage.
Leptin and Ghrelin Signaling Goes Haywire
Leptin tells your brain you're full. Ghrelin tells your brain you're hungry. Estrogen modulates both signals. When estrogen is stable, these hormones create a functional feedback loop — you eat, you feel satisfied, you stop. During perimenopause, this loop breaks. Leptin resistance develops (your brain stops hearing the "full" signal even though leptin levels are adequate). Ghrelin spikes become more frequent and intense. The subjective experience is constant low-grade hunger, food noise that won't quiet down, and a feeling of never being truly satisfied after meals. Women often describe this as a new relationship with food they didn't choose and don't understand. The mechanism is hormonal, not psychological.
NEAT Decreases
Non-exercise activity thermogenesis (NEAT) is the energy you burn through all the movement that isn't formal exercise: fidgeting, walking around the house, taking the stairs, gesturing while you talk, shifting in your chair. NEAT accounts for a surprisingly large portion of daily energy expenditure — often 200–500 calories per day. Estrogen influences NEAT through its effects on the central nervous system and overall energy levels. As estrogen declines, many women unconsciously move less. They sit more. Walk slower. Take the elevator. This isn't laziness — it's a neuroendocrine shift that reduces the drive to move. The caloric deficit this creates is significant over months and years.
The bottom line: Perimenopausal weight gain is not one thing going wrong. It's four or five things going wrong simultaneously, all driven by the same hormonal shift. That's why no single intervention — not a new diet, not more cardio, not "trying harder" — works the way it used to. The rules of your metabolism have fundamentally changed.
WHY DIETS STOP WORKING
Most women in perimenopause have been dieting, in one form or another, for 20+ years. They've done calorie restriction, keto, intermittent fasting, Whole30, Weight Watchers, and everything in between. Some of these worked — for a while. Then they stopped working. And then nothing worked.
This is not a failure of discipline. It's the predictable result of two compounding biological forces:
Metabolic Adaptation
Every time you restrict calories significantly, your body adapts. Your basal metabolic rate (BMR) — the energy you burn just existing — decreases. Your thyroid output shifts. Muscle mass decreases. The body becomes more metabolically efficient, which is a polite way of saying it learns to survive on less fuel. After years or decades of repeated dieting cycles, your BMR may be substantially lower than predicted for your age and weight. A woman who "should" burn 1,600 calories at rest might burn 1,300 because of accumulated metabolic adaptation. That 300-calorie gap makes traditional caloric restriction nearly impossible to sustain — you'd have to eat dangerously little to create a meaningful deficit.
Hormonal Shifts Compound the Problem
Metabolic adaptation alone is manageable for many people. But metabolic adaptation plus perimenopausal hormonal changes creates a compounding effect. Your BMR is already suppressed from years of dieting. Now estrogen decline suppresses it further. Your appetite regulation is already strained from chronic restriction. Now disrupted leptin and ghrelin signaling makes it worse. Your body was already good at storing fat. Now insulin resistance and the shift to visceral storage make it better. You're fighting on every front simultaneously, and the tools that used to work (eat less, move more) are no longer sufficient to overcome the combined resistance.
The Set-Point Problem
Your body defends a weight range. This "set point" is influenced by genetics, hormonal environment, and metabolic history. When you lose weight through caloric restriction alone, your body mounts a physiological counterattack: increased hunger hormones, decreased satiety hormones, reduced energy expenditure, and enhanced metabolic efficiency. These adaptations can persist for years after weight loss. During perimenopause, the set point appears to shift upward as the hormonal environment changes. Your body is now defending a higher weight with all the same biological intensity it used to defend your previous weight. Willpower is not designed to override this kind of sustained physiological pressure.
What this means practically: If you're a woman in perimenopause who feels like she's doing everything right and still gaining weight — you probably are doing everything right. The problem isn't your behavior. The problem is that the metabolic landscape has shifted underneath you, and behavioral interventions alone can't always compensate for hormonal and metabolic changes of this magnitude.
WHAT GLP-1 MEDICATIONS CAN DO
GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — are FDA-approved and available now. They work by addressing several of the exact mechanisms that make perimenopause weight gain so resistant to traditional approaches.
They Fix the Appetite Signal
GLP-1 agonists work directly on the hypothalamic appetite centers in the brain. They reduce the food noise — that constant background hum of hunger and craving that estrogen decline amplifies. Women on GLP-1s consistently report that the mental burden of food decisions drops dramatically. You can think about food normally again. This isn't suppressing appetite artificially — it's restoring the satiety signaling that hormonal changes disrupted.
They Improve Insulin Sensitivity
Both semaglutide and tirzepatide improve insulin dynamics. They enhance glucose-dependent insulin secretion (insulin goes up when blood sugar is high, stays normal when it's not) and reduce the chronically elevated insulin levels that drive visceral fat storage. For perimenopausal women whose insulin sensitivity is declining from estrogen loss, this directly counteracts one of the primary mechanisms behind abdominal weight gain. Tirzepatide's dual GLP-1/GIP action may offer an additional insulin-sensitizing benefit.
They Slow Gastric Emptying
GLP-1 agonists slow the rate at which food leaves your stomach. You feel full longer after meals. Portions that previously felt inadequate now feel satisfying. This isn't a side effect — it's a core mechanism. For women whose ghrelin signaling has been amplified by hormonal changes, the extended satiety is particularly impactful. You eat less not because you're white-knuckling through hunger, but because you're genuinely not hungry.
They Produce Real, Sustained Weight Loss
Semaglutide produces 15–20% body weight loss in clinical trials. Tirzepatide produces 20–25%. For a 180-pound woman, that's 27–45 pounds. This is not the 5–8 pounds that diet programs produce. This is clinically meaningful weight loss that changes metabolic markers, reduces cardiovascular risk, improves joint function, and restores quality of life. These medications work even in populations with high metabolic adaptation — because they're addressing the hormonal drivers, not just the caloric math.
The key insight: GLP-1 medications work because they operate on the same hormonal pathways that perimenopause has disrupted. They're not a willpower substitute. They're a pharmacological correction for a hormonal problem. That's why they succeed where "eat less, move more" fails.
WHERE RETATRUTIDE FITS
Retatrutide is an investigational triple-agonist developed by Eli Lilly. It activates three receptors simultaneously: GLP-1, GIP, and glucagon. It's currently in Phase 3 clinical trials (the TRIUMPH program) and is not FDA-approved or available for prescription.
What makes it relevant to perimenopause is the third receptor: glucagon.
The Glucagon Component Addresses Metabolic Slowdown
The central frustration of perimenopausal weight gain is the metabolic slowdown — your body burns fewer calories at rest and during activity. Existing GLP-1 medications primarily reduce caloric intake. They make you eat less. But they don't directly increase the rate at which you burn energy. Glucagon receptor activation does. It stimulates thermogenesis (heat production), increases hepatic fat oxidation (the liver burns its stored fat), and may increase resting energy expenditure. For a woman whose BMR has been suppressed by both years of dieting and estrogen decline, a medication that addresses the expenditure side of the equation — not just the intake side — is conceptually significant.
Phase 2 Data
In the Phase 2 trial (Jastreboff et al., NEJM 2023), participants on the highest dose (12 mg) lost an average of 24.2% of body weight over 48 weeks — the highest weight loss observed in any GLP-1 class trial to date. Phase 2 also showed an 86% relative reduction in liver fat, which is relevant because perimenopausal women have increased risk of fatty liver disease (MASLD) as estrogen's hepatoprotective effects decline.
Important Caveats
Phase 2 trials are small and preliminary. These results need confirmation in larger Phase 3 trials across diverse populations, including perimenopausal and postmenopausal women specifically. No published data exists yet on retatrutide's effects stratified by menopausal status. The mechanism is promising. The data is early. And no one can prescribe it yet regardless — it has not been approved by the FDA.
RETATRUTIDE AND FEMALE HORMONES
Whenever a new metabolic medication emerges, women need answers to questions that clinical trials weren't designed to ask. Here's what we know, what we can reason about, and what we honestly don't know yet.
Interaction with Estrogen and Progesterone
GLP-1 class medications do not directly affect estrogen or progesterone levels. They operate on incretin and glucagon pathways, not the hypothalamic-pituitary-ovarian axis. However, significant fat loss itself affects estrogen levels — adipose tissue produces estrone (a weaker estrogen) via aromatase. Losing a substantial amount of body fat reduces this peripheral estrogen production. For a postmenopausal woman on HRT, this is largely irrelevant because exogenous estrogen replaces what adipose tissue was producing. For a perimenopausal woman not on HRT, rapid fat loss could theoretically accelerate the decline in circulating estrogen. This is not unique to retatrutide — it applies to any effective weight loss intervention. But the more weight loss a drug produces, the more relevant it becomes.
Thyroid Considerations
GLP-1 medications carry a boxed warning about medullary thyroid carcinoma based on animal studies (observed in rodents at high doses, not confirmed in humans). For women already on levothyroxine for hypothyroidism or Hashimoto's — which is common in perimenopause — there's a practical interaction to be aware of: GLP-1 medications slow gastric emptying, which can affect the absorption timing of levothyroxine. This doesn't mean you can't take both. It means your provider should monitor TSH levels more closely after starting a GLP-1 and may need to adjust your levothyroxine dose or timing. The same consideration would apply to retatrutide if and when it's approved.
Birth Control Efficacy
This matters more than many providers acknowledge. Women in perimenopause can still ovulate unpredictably, and many use oral contraceptives for both contraception and hormone management. GLP-1 agonists slow gastric emptying, which can reduce the absorption of oral medications — including oral contraceptives. The FDA has acknowledged this interaction for tirzepatide specifically, recommending women switch to non-oral contraception or add a barrier method when initiating GLP-1 therapy. The same pharmacological mechanism would apply to retatrutide. If you're perimenopausal and relying on oral birth control, discuss this with your provider before starting any GLP-1 medication.
What We Don't Know
We don't have published data on retatrutide specifically in perimenopausal or menopausal women. Phase 2 and Phase 3 trials include women in these age groups, but results haven't been stratified by menopausal status. We don't know whether the glucagon component interacts differently with the hormonal milieu of perimenopause compared to premenopause. We don't know whether the magnitude of weight loss differs in this population. These are legitimate unknowns, and anyone claiming certainty about them is speculating.
THE MUSCLE QUESTION FOR WOMEN
This is the section that doesn't get enough attention. Women in perimenopause face a double threat to lean muscle mass — and adding a GLP-1 medication creates a potential third.
Threat 1: Perimenopause Itself
Estrogen is anabolic for muscle tissue. It supports muscle protein synthesis, reduces muscle protein breakdown, and supports mitochondrial function within muscle cells. As estrogen declines, women lose muscle mass at an accelerated rate. Studies suggest women can lose 0.5–1% of muscle mass per year during the menopausal transition — roughly double the rate of age-related sarcopenia in men. Declining testosterone (which also drops in perimenopause, though it gets less attention) compounds the problem. This muscle loss reduces BMR further, creating yet another layer of metabolic resistance to weight loss.
Threat 2: GLP-1 Medications
All significant weight loss — whether from surgery, medication, or caloric restriction — involves some loss of lean body mass. In clinical trials, roughly 25–40% of weight lost on GLP-1 medications is lean mass (including muscle). For semaglutide at the 2.4 mg dose, the STEP trials showed lean mass constituted about 39% of total weight lost. The ratio is concerning — but it's similar to what's observed with diet-induced weight loss at comparable levels. The issue is compounding: losing muscle on top of already-accelerated perimenopausal muscle loss is a real clinical risk.
Why This Matters More Than the Number on the Scale
Muscle mass determines your metabolic rate, your functional independence as you age, your bone density (muscle loading stimulates bone remodeling), your glucose disposal capacity (muscle is the primary site of insulin-mediated glucose uptake), and your fall risk. A woman who loses 40 pounds but half of it is muscle has not improved her metabolic health as much as the weight loss suggests. She may have lost weight but worsened her body composition. This is why we track body composition with DEXA scans, not just a scale.
Retatrutide's Potential Advantage
Retatrutide's glucagon receptor activation may offer a meaningful advantage here. Glucagon stimulates energy expenditure through fat oxidation — it preferentially mobilizes fat stores rather than lean tissue for energy. In Phase 2 data, the lean-to-fat loss ratio appeared more favorable than what's observed with GLP-1-only medications, though this needs confirmation in larger trials. The glucagon component may also support hepatic amino acid metabolism in ways that help preserve muscle protein. This is speculative based on mechanism — not proven in human data yet. But it's one of the strongest theoretical arguments for retatrutide in the perimenopausal population.
Non-negotiable regardless of medication: High protein intake (minimum 1.0–1.2 g/kg of ideal body weight daily) and progressive resistance training at least 2–3 times per week. These are not optional add-ons. They are the foundation that determines whether GLP-1-mediated weight loss improves your health or just changes your body weight while worsening your body composition. Every patient in our GLP-1 program receives guidance on both.
HRT + GLP-1: COMPLEMENTARY, NOT COMPETING
One of the most common misconceptions we encounter is that women need to choose between hormone replacement therapy and GLP-1 medication. That's like choosing between treating a broken arm and treating pneumonia. They're addressing different problems that happen to coexist.
What HRT Addresses
- • The underlying estrogen and progesterone decline
- • Vasomotor symptoms (hot flashes, night sweats)
- • Bone density preservation
- • Cardiovascular protection (when started within 10 years of menopause)
- • Improved insulin sensitivity (partially)
- • Mood, sleep, cognitive function, libido
- • Muscle preservation (estrogen is anabolic)
What GLP-1 Medications Address
- • Appetite dysregulation and food noise
- • Insulin resistance and hyperinsulinemia
- • Visceral fat reduction
- • Cardiovascular risk reduction (SELECT trial)
- • Hepatic fat reduction
- • Inflammatory marker improvement
- • Clinically significant weight loss (15–25%)
These interventions operate on different physiological axes. HRT restores the hormonal environment. GLP-1 medications correct the metabolic and appetite consequences that hormonal decline has already set in motion. Together, they address the full picture: the cause (hormone decline) and the downstream effects (weight gain, insulin resistance, visceral fat accumulation).
HRT alone often helps with weight gain — estrogen replacement improves insulin sensitivity and may shift fat distribution back toward subcutaneous rather than visceral. But for many women, HRT is not sufficient to reverse weight that's already been gained or overcome the metabolic adaptation from years of dieting. That's where GLP-1 medications fill the gap.
Similarly, GLP-1 medications alone can produce significant weight loss — but they don't address the hot flashes, bone density loss, sleep disruption, vaginal atrophy, mood changes, or the underlying hormonal deficiency that's driving half the problem.
Our approach: We don't force a choice. If you need both, we prescribe both. The combination of HRT + GLP-1 + resistance training + nutritional optimization addresses the hormonal transition comprehensively — not just the weight, and not just the symptoms.
WHAT MOONSHOT OFFERS TODAY
We treat the whole hormonal picture, not just weight. Every tool below is available now — no waiting for FDA approvals, no clinical trial enrollment required.
Hormone Replacement Therapy
Estradiol, progesterone, and testosterone replacement tailored to your labs, symptoms, and goals. Pellet, injectable, transdermal, and oral options. We treat perimenopause and menopause as the hormonal deficiency states they are — not as something to endure. Learn more about our women's hormone program.
GLP-1 Weight Loss Program
Semaglutide and tirzepatide prescribed as part of a comprehensive protocol — not a script-and-go operation. Includes dose titration, side effect management, nutritional guidance, and body composition tracking. We adjust based on your data, not a generic schedule. Explore our weight loss program.
DEXA Body Composition
A scale tells you what you weigh. A DEXA scan tells you what you're made of — how much is fat, how much is muscle, and where it's distributed. For women on GLP-1 medications, DEXA is essential: it tells us whether the weight you're losing is fat or muscle. We scan at baseline and at regular intervals to ensure your body composition is improving, not just your weight.
Comprehensive Blood Work
Full hormone panels (estradiol, progesterone, testosterone, DHEA-S, SHBG), thyroid (TSH, free T3, free T4, thyroid antibodies), metabolic markers (fasting insulin, glucose, HbA1c, lipid panel), inflammatory markers (hs-CRP), and micronutrients. We don't guess what's happening hormonally — we measure it. Learn about our blood work panels.
On retatrutide: When retatrutide receives FDA approval, we will evaluate it for our program. If the Phase 3 data and post-market safety profile support it, we'll make it available to patients for whom it's clinically appropriate — including perimenopausal and menopausal women. Until then, semaglutide and tirzepatide produce excellent results and are available now.
FREQUENTLY ASKED QUESTIONS
Why can't I lose weight during perimenopause?
Perimenopause triggers a cascade of hormonal changes that directly affect metabolism. Declining estrogen reduces insulin sensitivity (making your body store more fat, especially viscerally), alters leptin and ghrelin signaling (so hunger and satiety cues become unreliable), and decreases non-exercise activity thermogenesis. On top of that, years of caloric restriction have likely lowered your basal metabolic rate through metabolic adaptation. It's not willpower — it's endocrinology working against you on multiple fronts simultaneously.
Will retatrutide help with menopause weight gain?
Retatrutide's triple-agonist mechanism — particularly the glucagon receptor activation that increases energy expenditure — may be especially relevant for perimenopausal women whose metabolic rate has slowed. However, retatrutide is still in Phase 3 clinical trials and has not been approved by the FDA. It cannot be prescribed or purchased. FDA-approved GLP-1 medications like semaglutide and tirzepatide are available now and effectively address many of the same hormonal weight gain mechanisms.
Can I take GLP-1 medications with hormone replacement therapy?
Yes. GLP-1 medications and HRT work on different physiological axes and are generally considered complementary. HRT addresses the estrogen and progesterone decline driving many perimenopausal symptoms. GLP-1 medications address the metabolic and appetite dysregulation that contributes to weight gain. There are no known contraindications to combining them, though your provider should monitor you holistically. Moonshot Medical offers both and can coordinate your protocol.
Is weight gain during perimenopause permanent?
No — but it won't reverse on its own. The hormonal shifts of perimenopause create real physiological barriers to weight loss that weren't there in your 20s and 30s. Without addressing the underlying hormonal and metabolic changes, the weight typically stays or increases. With appropriate intervention — which may include HRT, GLP-1 medication, resistance training, and nutritional optimization — perimenopausal weight gain is treatable. The key is recognizing it as a medical issue, not a lifestyle failure.
When will retatrutide be available?
As of March 2026, retatrutide is in Phase 3 clinical trials (the TRIUMPH program by Eli Lilly). No FDA submission date has been announced. Based on typical timelines, the earliest possible approval would be late 2026 or 2027. Approval is not guaranteed. If you need treatment for weight gain now, FDA-approved options like semaglutide (Wegovy) and tirzepatide (Zepbound) are available and effective.
Does Moonshot Medical treat perimenopause?
Yes. Moonshot Medical offers comprehensive hormonal care for women in perimenopause and menopause, including hormone replacement therapy (estrogen, progesterone, testosterone), GLP-1 weight loss programs, DEXA body composition scanning, and full blood work panels. We treat the hormonal picture as a whole — not just isolated symptoms. Our clinic is located at 542 Busse Hwy in Park Ridge, IL and serves the greater Chicago area.
References
- 1. Jastreboff AM, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." N Engl J Med. 2023;389(6):514-526.
- 2. Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease." Nat Med. 2024;30:2037-2048.
- 3. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021;384:989-1002. (STEP 1)
- 4. Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387:205-216. (SURMOUNT-1)
- 5. Greendale GA, et al. "Changes in body composition and weight during the menopause transition." JCI Insight. 2019;4(5):e124865.
- 6. Mauvais-Jarvis F, et al. "The role of estrogens in control of energy balance and glucose homeostasis." Endocr Rev. 2013;34(3):309-338.
- 7. Marlatt KL, et al. "Body composition and cardiometabolic health across the menopause transition." Obesity. 2022;30(1):14-27.
- 8. Lovejoy JC, et al. "Increased visceral fat and decreased energy expenditure during the menopausal transition." Int J Obes. 2008;32(6):949-958.
- 9. Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity." N Engl J Med. 2023;389:2221-2232. (SELECT)
- 10. Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist." Cell Metab. 2022;34(9):1234-1247.
- 11. ClinicalTrials.gov: NCT05929066 (TRIUMPH Phase 3 program).
READY TO ADDRESS THE ROOT CAUSE?
Perimenopause changed the rules. We help you play by the new ones. Hormones, metabolism, body composition — we treat the whole picture, not just the scale.